The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
Rahul Raj Aggarwal
No relevant relationships to disclose
Vivian K. Weinberg
No relevant relationships to disclose
Charles J. Ryan
No relevant relationships to disclose
Andrea Harzstark
No relevant relationships to disclose
Alan H. Bryce
No relevant relationships to disclose
Christina Louise Derleth
No relevant relationships to disclose
Kimberly Lowe
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose